NASDAQ · MBAI

MBody AI Ltd.

Healthcare · Biotechnology

$6.39▲ 0.79% ($0.05)at close

As of 4:00 PM ET

52-week

$6.01$27.44

Market cap

$6.41M

P/E

1.37

EPS (TTM)

$4.65

Next earnings

May 15, 2026

What the market price implies · Reverse DCF

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$6.39

Estimated value / share

Unavailable

Base scenario

USD

Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.

Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.

Year 1 growth — · Ending margin — · Discount rate 9.46%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 20, 2026, 12:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: -63.63%FCF (YoY): 99.43%

What changed

The stock fell 63.63% over the last year. Free cash flow grew 99.43% year over year.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.

Performance

Return analysis

Company profile

MBody AI Ltd. designs and develops embodied artificial intelligence software for autonomous workforce and operational automation.

CEOJohn Fowler

SectorHealthcare

IndustryBiotechnology

Employees85

IPO dateMar 4, 2015

https://mbody.ai

Market multiples

Forward P/E—

EV/EBITDA2.32

Enterprise value$10.11M

Stock splits

Aug 13, 2026↓ Reverse

Every 7 shares became 1

-86%

Nov 25, 2022↓ Reverse

Every 20 shares became 1

-95%

Apr 4, 2018↓ Reverse

Every 12 shares became 1

-92%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROEN/A

Analyst consensus

Rating—

Target price—

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

May 15, 2026

Q1 FY24 · EPS est — · Revenue est —

View

Earnings history is still populating for this ticker.

NASDAQ · MBAI

MBody AI Ltd.

Healthcare · Biotechnology

$6.39▲ 0.79% ($0.05)at close

As of 4:00 PM ET

52-week

$6.01$27.44

Market cap

$6.41M

P/E

1.37

EPS (TTM)

$4.65

Next earnings

May 15, 2026

What the market price implies · Reverse DCF

Selected forecast · Base scenario

Unavailable · actual 10-year annualized revenue growth

Year 1 growth: —

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$6.39

Estimated value / share

Unavailable

Base scenario

USD

Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.

Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.

Year 1 growth — · Ending margin — · Discount rate 9.46%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 18, 2026, 8:00 PM UTC
Financial statement period: Not supplied
Data refreshed: Sep 20, 2026, 12:24 PM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.

1Y Price: -63.63%FCF (YoY): 99.43%

What changed

The stock fell 63.63% over the last year. Free cash flow grew 99.43% year over year.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.

What would invalidate this read

Performance

Return analysis

Company profile

MBody AI Ltd. designs and develops embodied artificial intelligence software for autonomous workforce and operational automation.

CEOJohn Fowler

SectorHealthcare

IndustryBiotechnology

Employees85

IPO dateMar 4, 2015

https://mbody.ai

Market multiples

Forward P/E—

EV/EBITDA2.32

Enterprise value$10.11M

Stock splits

Aug 13, 2026↓ Reverse

Every 7 shares became 1

-86%

Nov 25, 2022↓ Reverse

Every 20 shares became 1

-95%

Apr 4, 2018↓ Reverse

Every 12 shares became 1

-92%

Profitability & growth

Revenue growth—

Gross margin (TTM)0%

Operating margin (TTM)0%

ROEN/A

Analyst consensus

Rating—

Target price—

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

May 15, 2026

Q1 FY24 · EPS est — · Revenue est —

View

Earnings history is still populating for this ticker.